Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancer

  • Major change
  • Protocol
  • Intervention

Authors

  • Wahyu Wulaningsih,

    Corresponding author
    1. Tulip Integrated Cancer Clinic, Faculty of Medicine, Gadjah Mada University, Hematology/Oncology Division, Internal Medicine Department, Yogyakarta, Indonesia
    • Wahyu Wulaningsih, Hematology/Oncology Division, Internal Medicine Department, Tulip Integrated Cancer Clinic, Faculty of Medicine, Gadjah Mada University, Jalan Kesehatan No.1 Sekip Yogyakarta, Yogyakarta, Indonesia. wahyu.wulaningsih@yahoo.com.

    Search for more papers by this author
  • Ardyan Wardhana,

    1. International SOS, Yogyakarta, Indonesia
    Search for more papers by this author
  • Naomi Yoshuantari,

    1. Faculty of Medicine, Gadjah Mada University, Tulip Integrated Cancer Clinic, Hematology/Oncology Division, Internal Medicine Department, Yogyakarta, Indonesia
    Search for more papers by this author
  • Ajeng A Sekarini,

    1. Faculty of Medicine, Gadjah Mada University, Tulip Integrated Cancer Clinic, Hematology/Oncology Division, Internal Medicine Department, Yogyakarta, Indonesia
    Search for more papers by this author
  • Mieke Van Hemelrijck

    1. King?s College London, School of Medicine,, Division of Cancer Studies, Cancer Epidemiology Group, London, UK
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The aim of this systematic review is to compare efficacy and safety of two chemotherapeutic regimens, irinotecan monotherapy or irinotecan in combination with fluoropyrimidines, for patients with advanced colorectal cancer when administered in the first or second-line setting.